ArticleOncology letters2013
The CD79α (HM47/A9) antibody is effective in distinguishing between primary hepatocellular carcinoma and primary intrahepatic cholangiocarcinoma.
Article in Oncology letters, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 4 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are two major forms of primary liver cancer. The aim of this study was to investigate CD79α (HM47/A9) antibody expression patterns in normal liver, HCC and ICC samples. HM47/A9 expression was examined in tissues surrounding liver cancer in adults, 8-week embryos and 20-week embryos. In total, 82 cases of HCC, 31 cases of ICC and 11 cases of combined HCC and cholangiocarcinoma (cHCC-CC) were reviewed. HM47/A9 expression was observed as early as 8-week embryo liver tissue and exhibited focal granular cytoplasmic positivity, which was maintained throughout life. All 82 HCC cases demonstrated cytoplasmic granular positivity for HM47/A9, while no ICC cases were immunostained with HM47/A9. No CC components in cHCC-CC expressed the HM47/A9 antibody. A high number of HCC components in cHCC-CC showed positive staining for HM47/A9 [10/11 (90.9%)]. Our results suggest that HM47/A9 may be employed effectively to differentiate HCC from ICC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.